Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose bendamustine plus obinutuzumab in elderly follicular lymphoma
jRCTs031220727Recruiting
- Start
- Mar 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of obinutuzumab and bendamustine in follicular lymphoma (FL). Primary endpoint: Overall response rate. Started Mar 2023; status: recruiting.
02
Drugs
obinutuzumabbendamustine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCTs031220727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220727.